{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:30Z","timestamp":1791976110214,"version":"4.4.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.2169\/internalmedicine.4871-20","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T22:06:05Z","timestamp":1594073165000},"page":"2745-2749","source":"Crossref","is-referenced-by-count":7,"title":["The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia"],"prefix":"10.2169","volume":"59","author":[{"given":"Yasuhiro","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Hirase","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Sueda","sequence":"additional","affiliation":[{"name":"Department of Hematology, PL General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Luis","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan"},{"name":"Faculty of Medicine, UNIDES University, Nicaragua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Serizawa","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosaku","family":"Watatani","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Druker BJ, Guihot F, O&apos;Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006."},{"key":"2","unstructured":"2. Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K. Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-medicare data. Clin Lymphoma Myeloma Leuk 16: 275-285.e1, 2016."},{"key":"3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"3. Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126: 42-49, 2015.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sohn SK, Oh SJ, Kim BS, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 52: 1024-1029, 2011.","DOI":"10.3109\/10428194.2011.563885"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Giles FJ, Yin OQ, Sallas WM, et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 69: 813-823, 2013.","DOI":"10.1007\/s00228-012-1385-4"},{"key":"6","unstructured":"6. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 10: 85-97, 2013."},{"key":"7","unstructured":"7. Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res 48: 84-91, 2016."},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"9","unstructured":"9. Sprycel<sup>\u00ae<\/sup> (dasatinib) [package insert]. Bristol-Myers Squibb Company [Internet]. [cited 2019 Nov 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf"},{"key":"10","unstructured":"10. Sprycel<sup>\u00ae<\/sup> (dasatinib) [package insert]. Bristol-Myers Squibb Company [Internet]. [cited 2019 Nov 19]. Available from: https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/670605_4291020F1027_1_013_1F.pdf (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Abbas R, Chalson S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 71: 123-132, 2013.","DOI":"10.1007\/s00280-012-1987-7"},{"key":"12","unstructured":"12. Bosulif (bosutinib) [package insert]. Pfizer [Internet]. [cited 2019 Nov 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/20334s007s008lbl.pdf"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Leblond FA, Guevin C, Demers C, Pellerin I, Gascon-Barr\u00e9 M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001.","DOI":"10.1681\/ASN.V122326"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Leblond FA, Petrucci M, Dub\u00e9 P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13: 1579-1585, 2002.","DOI":"10.1097\/01.ASN.0000017575.50319.77"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73: 427-434, 2003.","DOI":"10.1016\/S0009-9236(03)00056-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pappas P, Karavasillis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 56: 358-360, 2005.","DOI":"10.1007\/s00280-005-1031-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol 81: 474, 2006.","DOI":"10.1002\/ajh.20620"},{"key":"18","unstructured":"18. Wada Y, Ogata H, Misawa S, Shimada A, Kinugasa E. A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate. Intern Med 51: 1561-1565, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Niikura R, Serizwa T, Yamada A, et al. Safety of regular-dose imatinib therapy in patients with gastrointestinal stromal tumors undergoing dialysis. Case Rep Gastroenterol 10: 17-23, 2016.","DOI":"10.1159\/000443267"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Onaka T, Takahashi N, Miura M, Yonezawa A, Imada K, Sawada K. Pharmacokinetics of nilotinib in imatinib-resistant\/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. Am J Hematol 87: 451, 2012.","DOI":"10.1002\/ajh.23125"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33: 344-347, 2009.","DOI":"10.1016\/j.leukres.2008.07.029"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shibazaki S, Tsuda K, Araki M, Yamasaki M, Miura K. A case of long-term survival from chronic myeloid leukemia in a hemodialysis patient receiving imatinib and experiencing cardiotoxicity with dasatinib. Nihon Toseki Igakkai Zassi (J Jpn Soc Dalysis Therapy) 48: 713-718, 2015 (in Japanese, Abstract in English).","DOI":"10.4009\/jsdt.48.713"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mori J, Oshima K, Tanimoto T, et al. Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. Int J Hematol 112: 115-117, 2020.","DOI":"10.1007\/s12185-020-02846-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_4871-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T13:28:55Z","timestamp":1667309335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_4871-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4871-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}